Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06786897

Expectations of Patients in Palliative Situation

To date, there is a lack of data about the benefit of blood cell transfusions for patients diagnosed of a hematologic malignancy who are not eligible for curative treatments. Furthermore, there is no clear guideline about how to transfuse these patients and when the blood cell transfusions should be stopped.

Allogenic stem cell transplantation is nowadays the only curative treatment for patients with high-risk myeloid neoplasms. Knowing that the median age at diagnostic for acute myeloid leukemia is 68 years and this incidence increases after 65 years, a lot of patients won't be eligible for allogenic stem cell transplantation.

Besides, patients with haematologic malignancies are prone to cytopenias, due to their pathology and the treatments used to limit its progression. A study estimate that these patients need a median of 4 blood cell units per month, and it is known that repeated transfusions are associated with an increased risk of dying in hospital.

Finally, it is estimate that there was a lack of 20 000 blood cell units in France in 2022.

It therefore seems essential to find ways to optimize blood transfusion prescriptions in this population of patients who won't be eligible for curative treatments, with the main idea of maintaining or even improving their quality of life.

The investigators will study the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions, by asking them if whether or not they believe that the transfusion planed to be administer will benefit the patient. To do this, investigators will distribute questionnaires before each blood cell transfusions to patients who will be included, to the paramedic who administered the transfusion and to the physician who prescribed the transfusion.

It is to investigators knowledge the first study to compare the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions in hematology department, and follow the evolution of these expectations prospectively.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UH Montpellier

Montpellier, 34000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 years or more AND
  • Diagnosed of an intermediate or high-risk acute leukemia and not eligible for allogenic stem cell transplantation Or
  • Diagnosed of a high-risk myelodisplasic syndrome and not eligible for allogenic stem cell transplantation Or
  • Diagnosed of an intermediate or high-risk myelofibrosis and not eligible for allogenic stem cell transplantation Or
  • Diagnosed of a chronic myeloid leukemia in blast crisis phase and not eligible for allogenic stem cell transplantation Or
  • Relapsing after allogenic stem cell transplantation and not eligible for a second allogenic stem cell transplantation

Exclusion criteria

  • Patients who can't read
  • Patients who can't write
  • Patients who can't express their consent

Treatment and study plan

Questionnaire and Physical Exam

Other

Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.

Primary outcomes

  1. Evaluation of the benefit of blood cell transfusion before each blood cell transfusion

    Time frame: up to 52 weeks

    Evaluate the concordance for the perceptions of the benefit of blood cell transfusions in a palliative situation in hematology department between patients, paramedical and medical staff

Secondary outcomes

  1. Number of days before death

    Time frame: through study completion, an average of 1 year

    Define the median number of days before death, from which patients believe they no longer benefit from blood transfusions

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Expectations of Patients in Palliative Situation and Their Caregivers Concerning Blood Cell Transfusions in Haematology Department

Acronym: ERAPH

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jan 22, 2025
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.